Harrow Health Inc.

10/10/2024 | Press release | Distributed by Public on 10/10/2024 05:05

Melt Pharmaceuticals Announces Dosing of Last Patient in Pivotal Phase 3 Study of Its Lead Product Candidate, MELT 300, for Needle and Opioid Free Sedation in Patients[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.